DK1592401T3 - Fremgangsmåde til ændring af medikamentkrystaldannelsen af mycophenolat-natriumsalt - Google Patents

Fremgangsmåde til ændring af medikamentkrystaldannelsen af mycophenolat-natriumsalt

Info

Publication number
DK1592401T3
DK1592401T3 DK04703158.8T DK04703158T DK1592401T3 DK 1592401 T3 DK1592401 T3 DK 1592401T3 DK 04703158 T DK04703158 T DK 04703158T DK 1592401 T3 DK1592401 T3 DK 1592401T3
Authority
DK
Denmark
Prior art keywords
altering
sodium salt
crystal formation
mycophenolate sodium
drug crystal
Prior art date
Application number
DK04703158.8T
Other languages
English (en)
Inventor
Sabine Pfeffer
Dierk Wieckhusen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9951448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1592401(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1592401T3 publication Critical patent/DK1592401T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
DK04703158.8T 2003-01-20 2004-01-19 Fremgangsmåde til ændring af medikamentkrystaldannelsen af mycophenolat-natriumsalt DK1592401T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0301259.8A GB0301259D0 (en) 2003-01-20 2003-01-20 Organic compounds
PCT/EP2004/000354 WO2004064806A2 (en) 2003-01-20 2004-01-19 Process for modifying drug crystal formation

Publications (1)

Publication Number Publication Date
DK1592401T3 true DK1592401T3 (da) 2012-05-21

Family

ID=9951448

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04703158.8T DK1592401T3 (da) 2003-01-20 2004-01-19 Fremgangsmåde til ændring af medikamentkrystaldannelsen af mycophenolat-natriumsalt

Country Status (32)

Country Link
US (3) US20060122265A1 (da)
EP (2) EP2308471A1 (da)
JP (1) JP4549976B2 (da)
KR (5) KR100855149B1 (da)
CN (2) CN100595199C (da)
AR (2) AR043343A1 (da)
AT (1) ATE546132T1 (da)
AU (1) AU2004206731B2 (da)
BR (1) BRPI0406827A (da)
CA (2) CA2706900A1 (da)
CL (1) CL2004000073A1 (da)
CO (1) CO5580738A2 (da)
CY (1) CY1112772T1 (da)
DK (1) DK1592401T3 (da)
EC (1) ECSP055918A (da)
ES (1) ES2382035T3 (da)
GB (1) GB0301259D0 (da)
HK (1) HK1084874A1 (da)
IL (1) IL169484A (da)
MX (1) MXPA05007691A (da)
MY (1) MY148297A (da)
NO (1) NO20053846L (da)
NZ (1) NZ541073A (da)
PE (2) PE20110276A1 (da)
PL (2) PL376525A1 (da)
PT (1) PT1592401E (da)
RU (1) RU2388757C2 (da)
SG (1) SG155046A1 (da)
SI (1) SI1592401T1 (da)
TW (1) TWI325785B (da)
WO (1) WO2004064806A2 (da)
ZA (1) ZA200504442B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
JP2007532585A (ja) 2004-04-26 2007-11-15 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ ミコフェノール酸及びそのエステル誘導体の調製方法
WO2005105769A2 (en) 2004-04-27 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg - Mycophenolate mofetil impurity
CA2573781A1 (en) 2004-07-20 2006-02-02 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Processes for preparation of crystalline mycophenolate sodium
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US20080176937A1 (en) * 2007-01-23 2008-07-24 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
BRPI0823092A2 (pt) * 2008-10-09 2015-09-29 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi método de granulação úmida de moxifloxacin anídrico ou seus sais
CN101756958B (zh) * 2008-11-10 2011-07-20 鲁南制药集团股份有限公司 一种治疗关节炎的药物组合物及其制备方法
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
AU2010270202B2 (en) * 2009-07-10 2014-04-24 Janssen Pharmaceutica Nv Crystallisation process for 1-(beta-D-glucopyranosyl)-4-methyl-3- [5-(4-fluorophenyl)-2-thienylmethyl] benzene
EP2488173A1 (en) * 2009-10-13 2012-08-22 Teva Pharmaceutical Industries Ltd. Delayed release compositions
EP4148045A1 (en) 2010-01-27 2023-03-15 Arena Pharmaceuticals, Inc. Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof
JP6227406B2 (ja) 2010-05-11 2017-11-08 ヤンセン ファーマシューティカ エヌ．ベー． ＳＧＬＴの阻害剤としての１−（β−Ｄ−グルコピラノシル）−２−チエニル−メチルベンゼン誘導体を含有する医薬製剤
CN103880800A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103880799A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
WO2012140120A1 (en) 2011-04-13 2012-10-18 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
TWI582078B (zh) * 2013-01-23 2017-05-11 北京貝美拓新藥研發有限公司 抑制脯氨酸羥化酶活性的化合物的晶型及其應用
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
PL3394051T3 (pl) * 2015-12-21 2020-10-19 Janssen Pharmaceutica N.V. Procedura krystalizacji do otrzymywania kryształów półwodnej kanagliflozyny
CN110545848A (zh) 2017-02-16 2019-12-06 艾尼纳制药公司 用于治疗具有肠外表现的炎症性肠病的化合物和方法
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
CN108727318A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 麦考酚酸的晶型物
CN108727317A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 一种麦考酚酸的晶型物
CN110922371B (zh) * 2019-12-27 2020-08-11 广东蓝宝制药有限公司 一种m2晶型麦考酚钠的制备方法
WO2023234158A1 (ja) * 2022-05-31 2023-12-07 本州化学工業株式会社 ４，４'－ビス（１，１－ビス（４－ヒドロキシ－３－メチルフェニル）エチル）ビフェニルの結晶及び、その製造方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US158835A (en) * 1875-01-19 Improvement in mortising-tools
GB935432A (en) * 1958-05-29 1963-08-28 Secr Aviation Improvements in the manufacture of crystalline substances
US3183263A (en) * 1962-10-19 1965-05-11 Commercial Solvents Corp Method for changing the crystal habit of mono-sodium glutamate
US3187039A (en) * 1962-10-19 1965-06-01 Commercial Solvents Corp Method for changing the crystal habit of monosodium glutamate
US3352906A (en) * 1963-02-04 1967-11-14 Charles R Parkerson Habit modification and preparation of single crystal triglycine sulfate
US3770390A (en) * 1971-02-26 1973-11-06 Dow Chemical Co Crystal habit modification of inorganic salts using polymeric sulfonates or sulfates
US4259239A (en) * 1980-04-21 1981-03-31 Allied Chemical Corporation Resolution of enantiomeric complexes of nickelous chloride and alpha-aminocaprolactam
IL60254A (en) 1980-06-08 1983-11-30 Yeda Res & Dev Resolution of amino acids
JPS5875194A (ja) * 1981-10-30 1983-05-06 株式会社日立製作所 マトリクス表示装置及び駆動方法
JPS59232916A (ja) * 1983-06-16 1984-12-27 Shiraishi Chuo Kenkyusho:Kk 針柱状炭酸カルシウム結束体、その製造法及び該結束体を含有する感熱紙用塗被組成物
IL77031A (en) 1985-11-12 1995-12-08 Yeda Res & Dev Kinetic resolution of racemic mixtures by polymer-bound crystallization inhibitors
JPH0745359B2 (ja) 1987-12-25 1995-05-17 東レ株式会社 有機化合物結晶の製造方法
EP0582452B1 (en) * 1992-08-04 1998-10-14 Toda Kogyo Corp. Granulated particles for magnetic particles for magnetic recording and process for producing the same
DE69414720T2 (de) 1993-09-15 1999-04-08 Syntex Inc Kristallines, wasserfreies mofetilmycophenolat und zubereitungen zu deren intravenösen anwendung
JPH09209297A (ja) * 1996-01-26 1997-08-12 Nippon Paper Ind Co Ltd 艶消し軽量塗工紙及びその製造方法
KR100491274B1 (ko) * 1996-04-12 2005-09-05 노파르티스 아게 미코페놀레이트의장용코팅된약제조성물
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
FR2780403B3 (fr) * 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AU2004206731B2 (en) 2008-03-20
PE20040826A1 (es) 2004-12-23
AR043343A1 (es) 2005-07-27
AU2004206731A8 (en) 2004-08-05
PT1592401E (pt) 2012-05-10
ES2382035T3 (es) 2012-06-04
EP2308471A1 (en) 2011-04-13
US8124795B2 (en) 2012-02-28
AU2004206731A1 (en) 2004-08-05
KR100855149B1 (ko) 2008-08-28
RU2388757C2 (ru) 2010-05-10
TWI325785B (en) 2010-06-11
ATE546132T1 (de) 2012-03-15
JP4549976B2 (ja) 2010-09-22
CL2004000073A1 (es) 2005-01-14
TW200505505A (en) 2005-02-16
CN1738605A (zh) 2006-02-22
SI1592401T1 (sl) 2012-05-31
CN100595199C (zh) 2010-03-24
EP1592401A2 (en) 2005-11-09
BRPI0406827A (pt) 2005-12-27
PL213192B1 (pl) 2013-01-31
US8008511B2 (en) 2011-08-30
KR20050096940A (ko) 2005-10-06
SG155046A1 (en) 2009-09-30
US20090209639A1 (en) 2009-08-20
MY148297A (en) 2013-03-29
CA2509796C (en) 2010-09-14
ZA200504442B (en) 2006-02-22
KR101129105B1 (ko) 2012-04-12
ECSP055918A (es) 2005-11-22
KR20090115821A (ko) 2009-11-06
CA2509796A1 (en) 2004-08-05
PL376525A1 (pl) 2006-01-09
JP2006515016A (ja) 2006-05-18
NO20053846L (no) 2005-08-16
RU2005126328A (ru) 2006-07-27
EP1592401B1 (en) 2012-02-22
HK1084874A1 (en) 2006-08-11
CN101333201A (zh) 2008-12-31
PE20110276A1 (es) 2011-05-27
NZ541073A (en) 2008-12-24
IL169484A (en) 2016-03-31
WO2004064806A3 (en) 2004-10-28
CA2706900A1 (en) 2004-08-05
KR20090115898A (ko) 2009-11-09
MXPA05007691A (es) 2005-09-30
IL169484A0 (en) 2007-07-04
GB0301259D0 (en) 2003-02-19
KR20100120321A (ko) 2010-11-15
PL393385A1 (pl) 2011-03-14
WO2004064806A2 (en) 2004-08-05
CY1112772T1 (el) 2016-02-10
US20110288313A1 (en) 2011-11-24
US20060122265A1 (en) 2006-06-08
KR20070087181A (ko) 2007-08-27
CO5580738A2 (es) 2005-11-30
AR103711A2 (es) 2017-05-31

Similar Documents

Publication Publication Date Title
DK1592401T3 (da) Fremgangsmåde til ændring af medikamentkrystaldannelsen af mycophenolat-natriumsalt
DK1539711T3 (da) Fremgangsmåde til fremstilling af calciumsaltet af rosuvastatin
DK1651622T3 (da) Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1720571T3 (da) Fremgangsmåde til behandling af hæmolytisk sygdom
NO20070753L (no) Fremgangsmåte for fremstilling av dihydropteridinoner
DK3225233T3 (da) Natriumchloridopløsning til rekonstituering af lægemiddel
IS8217A (is) Bætt framleiðsla rósúvastatínkalsíumsalts
DK1611108T3 (da) Fremgangsmåde til fremstilling af telmisartan
FI20021251A0 (fi) Menetelmä betaiinin talteenottamiseksi
IS8122A (is) Aðferð til að framleiða N-útskipt 2-sýanópýrrólídín
DK1546122T3 (da) Fremgangsmåde til fremstilling af valsartan
DK1622612T3 (da) Farmaceutisk formulering af natriumsaltet af telmitarsan
IS2674B (is) Aðferð við framleiðslu á handhverfulega hreinu mírtasapíni
DK1831223T3 (da) Fremgangsmåde til fremstilling af L-biopterin
DK1667967T3 (da) Fremgangsmåde til fremstilling af 2-oxo-1-pyrrolidin-derivater
DK1682543T3 (da) Fremgangsmåde til fremstilling af nye tiotropiumsalte
DK1805316T3 (da) Fremgangsmåde til fremstilling af de enantiomere former af cis-3-hydroxycy-
NO20044814L (no) Fremgangsmate for fremstilling av combretastaniner
NO20041850L (no) Fremgangsmate for dannelse av profenkrystaller
DK1678135T3 (da) Fremgangsm de til fremstilling af n-amino-substituerede hetorocykliske forbindelser
DK1682541T3 (da) Fremgangsmåde til fremstilling af tiotropiumsalte
DK1575941T3 (da) Fremgangsmåde til fremstilling af (S)-pantoprazol
DK1937662T3 (da) Fremgangsmåde til fremstilling af duloxetin
DK1511724T3 (da) Fremgangsmåde til fremstilling af thioalkylaminderivater